Logo image of PLUR

PLURI INC (PLUR) Stock Fundamental Analysis

NASDAQ:PLUR - Nasdaq - US72942G2030 - Common Stock - Currency: USD

4.03  +0.41 (+11.33%)

Fundamental Rating

2

PLUR gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. PLUR may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, PLUR is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

PLUR had negative earnings in the past year.
PLUR had a negative operating cash flow in the past year.
In the past 5 years PLUR always reported negative net income.
PLUR had a negative operating cash flow in each of the past 5 years.
PLUR Yearly Net Income VS EBIT VS OCF VS FCFPLUR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

PLUR has a worse Return On Assets (-64.35%) than 62.68% of its industry peers.
Industry RankSector Rank
ROA -64.35%
ROE N/A
ROIC N/A
ROA(3y)-56.83%
ROA(5y)-53.66%
ROE(3y)-7370.79%
ROE(5y)-4450.32%
ROIC(3y)N/A
ROIC(5y)N/A
PLUR Yearly ROA, ROE, ROICPLUR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K

1.3 Margins

The Gross Margin of PLUR (47.49%) is better than 75.88% of its industry peers.
In the last couple of years the Gross Margin of PLUR has remained more or less at the same level.
PLUR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 47.49%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y0.51%
PLUR Yearly Profit, Operating, Gross MarginsPLUR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K -100K

More info and screens

2

2. Health

2.1 Basic Checks

PLUR does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for PLUR has been increased compared to 1 year ago.
PLUR has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, PLUR has a worse debt to assets ratio.
PLUR Yearly Shares OutstandingPLUR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M
PLUR Yearly Total Debt VS Total AssetsPLUR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -20.64, we must say that PLUR is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -20.64, PLUR is doing worse than 86.44% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -20.64
ROIC/WACCN/A
WACC8.02%
PLUR Yearly LT Debt VS Equity VS FCFPLUR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

PLUR has a Current Ratio of 5.04. This indicates that PLUR is financially healthy and has no problem in meeting its short term obligations.
PLUR has a Current ratio (5.04) which is in line with its industry peers.
PLUR has a Quick Ratio of 5.04. This indicates that PLUR is financially healthy and has no problem in meeting its short term obligations.
PLUR has a Quick ratio (5.04) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 5.04
Quick Ratio 5.04
PLUR Yearly Current Assets VS Current LiabilitesPLUR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 21.93% over the past year.
The Revenue has grown by 89.92% in the past year. This is a very strong growth!
The Revenue has been growing by 43.27% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)21.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.37%
Revenue 1Y (TTM)89.92%
Revenue growth 3YN/A
Revenue growth 5Y43.27%
Sales Q2Q%76.19%

3.2 Future

PLUR is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -22.20% yearly.
PLUR is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 254.68% yearly.
EPS Next Y-162.5%
EPS Next 2Y-43.47%
EPS Next 3Y-22.2%
EPS Next 5YN/A
Revenue Next Year472.39%
Revenue Next 2Y350.32%
Revenue Next 3Y254.68%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
PLUR Yearly Revenue VS EstimatesPLUR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2018 2019 2020 2022 2023 2024 2025 2026 2027 5M 10M
PLUR Yearly EPS VS EstimatesPLUR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -10 -20 -30 -40

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

PLUR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PLUR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PLUR Price Earnings VS Forward Price EarningsPLUR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PLUR Per share dataPLUR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

PLUR's earnings are expected to decrease with -22.20% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-43.47%
EPS Next 3Y-22.2%

More info and screens

0

5. Dividend

5.1 Amount

PLUR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PLURI INC

NASDAQ:PLUR (4/17/2025, 8:00:00 PM)

4.03

+0.41 (+11.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-10 2025-02-10
Earnings (Next)05-07 2025-05-07
Inst Owners10.42%
Inst Owner Change-0.01%
Ins Owners10.49%
Ins Owner Change36.05%
Market Cap28.21M
Analysts82.86
Price TargetN/A
Short Float %0.64%
Short Ratio2.5
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-3050%
EPS NY rev (3m)-3050%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 41.61
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.68
EYN/A
EPS(NY)-2.52
Fwd EYN/A
FCF(TTM)-2.52
FCFYN/A
OCF(TTM)-2.46
OCFYN/A
SpS0.1
BVpS-1.15
TBVpS-1.15
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -64.35%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 47.49%
FCFM N/A
ROA(3y)-56.83%
ROA(5y)-53.66%
ROE(3y)-7370.79%
ROE(5y)-4450.32%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y0.51%
F-Score2
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 164.31%
Cap/Sales 61.8%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.04
Quick Ratio 5.04
Altman-Z -20.64
F-Score2
WACC8.02%
ROIC/WACCN/A
Cap/Depr(3y)75.54%
Cap/Depr(5y)54.21%
Cap/Sales(3y)103.34%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.37%
EPS Next Y-162.5%
EPS Next 2Y-43.47%
EPS Next 3Y-22.2%
EPS Next 5YN/A
Revenue 1Y (TTM)89.92%
Revenue growth 3YN/A
Revenue growth 5Y43.27%
Sales Q2Q%76.19%
Revenue Next Year472.39%
Revenue Next 2Y350.32%
Revenue Next 3Y254.68%
Revenue Next 5YN/A
EBIT growth 1Y10.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y45.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y45.78%
OCF growth 3YN/A
OCF growth 5YN/A